KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of ...

Citizens Jmp upgraded shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) to a strong-buy rating in a report ...

JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...

CAMBRIDGE, Mass. & SALISBURY, England, February 04, 2025--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted ...

Fintel reports that on January 31, 2025, JMP Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...

JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 14,400 shares of the stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.26, for a ...

TD Cowen initiated coverage of KalVista (KALV) with a Buy rating and $30 price target The firm cites sebetralstat’s opportunity as the first oral acute therapy for hereditary angioedema attacks ...

KalVista Pharma has filed its first marketing application to the US FDA, seeking approval for its oral plasma kallikrein inhibitor sebetralstat as an oral treatment for hereditary angioedema (HAE ...